This Biotech Stock Could Cure Your Portfolio's Pain

Investors seeking a biotech stock with significant upside potential to add to their portfolio may want to consider Arcutis Biotherapeutics (NASDAQ: ARQT). The stock price is already up 112% in 2025, as I write, but there could be more to come in the next few years. Here's why.The company's primary product is Zoryve, a non-steroidal topical medication available in cream and foam formulations, which treats a variety of inflammatory skin diseases, including plaque psoriasis, atopic dermatitis (also known as eczema), and seborrheic dermatitis. It contains the active ingredient roflumilast, a PDE4 inhibitor that reduces the skin's inflammatory response.Arcutis has already received approval across a range of applications and indications, with the next approval likely to be for Zoryve cream in children aged two to five years old. Arcutis also has Zoryve in phase 2 trials for three other indications/concentrations.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool